These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 28903105)

  • 1. Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation and/or Transcatheter Arterial Chemoembolization: A Propensity Score-Matched Analysis.
    Orimo T; Kamiyama T; Yokoo H; Wakayama K; Shimada S; Einama T; Kamachi H; Taketomi A
    Dig Surg; 2018; 35(5):427-434. PubMed ID: 28903105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.
    Peng Z; Wei M; Chen S; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Kuang M
    Eur Radiol; 2018 Aug; 28(8):3522-3531. PubMed ID: 29536241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study.
    Wang C; Liao Y; Qiu J; Yuan Y; Zhang Y; Li K; Zou R; Wang Y; Zuo D; He W; Zheng Y; Li B; Yuan Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2669-2680. PubMed ID: 32449005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma.
    Endo K; Kuroda H; Oikawa T; Okada Y; Fujiwara Y; Abe T; Sato H; Sawara K; Takikawa Y
    Scand J Gastroenterol; 2018 Dec; 53(12):1575-1583. PubMed ID: 30577723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of adjuvant transcatheter arterial chemoembolization following repeated curative resection/ablation for hepatocellular carcinoma with early recurrence: a propensity score matching analysis.
    Huang K; Qian T; Chen W; Lao M; Li H; Lin WC; Chen BW; Bai X; Gao S; Ma T; Liang T
    BMC Cancer; 2024 May; 24(1):620. PubMed ID: 38773564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
    Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
    BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis.
    Koh PS; Chan AC; Cheung TT; Chok KS; Dai WC; Poon RT; Lo CM
    HPB (Oxford); 2016 Jan; 18(1):72-8. PubMed ID: 26776854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.
    Bai XM; Cui M; Yang W; Wang H; Wang S; Zhang ZY; Wu W; Chen MH; Yan K; Goldberg SN
    Radiology; 2021 Aug; 300(2):458-469. PubMed ID: 34003058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
    Liu C; Sun L; Xu J; Zhao Y
    World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods.
    Kuo MJ; Mo LR; Chen CL
    BMC Cancer; 2021 Mar; 21(1):250. PubMed ID: 33685409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of preoperative TACE on incidences of microvascular invasion and long-term post-hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis.
    Yang Y; Lin K; Liu L; Qian Y; Yang Y; Yuan S; Zhu P; Huang J; Liu F; Gu F; Fu S; Jiang B; Liu H; Pan Z; Lau WY; Zhou W
    Cancer Med; 2021 Mar; 10(6):2100-2111. PubMed ID: 33650288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
    Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
    Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis.
    Li C; Wang MD; Lu L; Wu H; Yu JJ; Zhang WG; Pawlik TM; Zhang YM; Zhou YH; Gu WM; Wang H; Chen TH; Han J; Xing H; Li ZL; Lau WY; Wu MC; Shen F; Yang T
    Hepatol Int; 2019 Nov; 13(6):736-747. PubMed ID: 31486964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence of microvascular invasion guides treatment strategy in recurrent HBV-related HCC.
    Chen SL; Xiao H; Xie ZL; Shen JX; Chen ZB; Wang YQ; Li B; Peng ZW; Kuang M; Lai JM; Peng S
    Eur Radiol; 2020 Jun; 30(6):3473-3485. PubMed ID: 32048035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical efficiency of TACE combined with simultaneous computed tomography-guided radiofrequency ablation for advanced hepatocellular carcinoma.
    Yuan P; Wang F; Zhu G; Chen B
    Invest New Drugs; 2021 Oct; 39(5):1383-1388. PubMed ID: 33754235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoembolization versus radiofrequency ablation for single small (≤ 3 cm) hepatocellular carcinoma: a propensity score matching analysis.
    Kim GH; Kim JH; Shim JH; Kim SY; Kim PH; Ko HK; Gwon DI; Shin JH; Lee SJ; Chu HH; Won HJ; Shin YM; Kim N
    Eur Radiol; 2024 Sep; 34(9):5517-5528. PubMed ID: 38329504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: Propensity score analyses of long-term outcomes.
    Lee S; Kang TW; Cha DI; Song KD; Lee MW; Rhim H; Lim HK; Sinn DH; Kim JM; Kim K
    J Hepatol; 2018 Jul; 69(1):70-78. PubMed ID: 29524532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion.
    Jin YJ; Lee JW; Lee OH; Chung HJ; Kim YS; Lee JI; Cho SG; Jeon YS; Lee KY; Ahn SI; Shin WY
    J Gastroenterol Hepatol; 2014 May; 29(5):1056-64. PubMed ID: 24372785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis.
    Hsu CY; Huang YH; Chiou YY; Su CW; Lin HC; Lee RC; Chiang JH; Huo TI; Lee FY; Lee SD
    Liver Transpl; 2011 May; 17(5):556-66. PubMed ID: 21506244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.